Breaking News


Ustekinumab yields sustained response in phase II and III trials in plaque psoriasis


Centocor Ortho Biotech reported at the Summer Meeting of the American Academy of Dermatology held in Chicago that new study findings have shown that a majority of patients with moderate to severe plaque psoriasis who had a previous response to ustekinumab (CNTO-1275, Stelara[R]), a human monoclonal antibody that targets interleukin (IL)-12 and IL-23, sustained a clinical response for up to 3 years with continued treatment, regardless of the subjects' body weight. Investigators also presented findings from an integrated safety analysis that included data from one phase II and three phase III trials in which treatment with ustekinumab demonstrated a favorable benefit-to-risk profile for up to 3 years of treatment, consistent with ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list